Skip to content

Comparing effects of two different treatments in participants with vitiligo

Efficacy of Platelet Rich Plasma and 308nm Excimer laser versus 308nm Excimer laser alone in stable vitiligo patients - Nil

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/03/082114
Enrollment
45
Registered
2025-03-11
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L80- Vitiligo

Interventions

Intervention1: PLATELET RICH PLASMA AND 308nm EXCIMER LASER: PLATELET RICH PLASMA FOR A LESION AND EXCIMER LASER PLUS PLATELET RICH PLASMA FOR OTHER SYMMETRICAL/EQUAL LESION. Intervention2: Platelet R

Sponsors

GSL Medical College
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)Patients aged 18-60 years. 2)Vitiligo patients with stable lesions for at least one year. 3)Patients who are willing to give consent.

Exclusion criteria

Exclusion criteria: 1)Patients with unstable vitiligo. 2)Patients who are not willing to give consent. 3)Infections. 4)Patients with bleeding disorders. 5)Patients on anticoagulants. 6)Pregnant and breastfeeding women. 7)Patients with history of skin cancer, keloid, hypertrophic scar, psoriasis, lichen planus, photosensitivity disorders and Koebner’s phenomenon.

Design outcomes

Primary

MeasureTime frame
This study is expected to reveal the efficacy of combining Platelet Rich Plasma with 308-nm Excimer laser therapy compared to 308-nm Excimer laser therapy alone in Stable Vitiligo lesions.Timepoint: Baseline and after 4 months

Secondary

MeasureTime frame
Side effects will be noted for both Platelet Rich Plasma & Excimer Laser treatments during each visitTimepoint: Baseline & weekly twice for 4 months

Countries

India

Contacts

Public ContactKARNATI LAKSHMI VENKATA VIKRAMNATH REDDY

GSL MEDICAL COLLEGE AND GENERAL HOSPITAL

aidsandsex@rocketmail.com9246345937

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026